Development and characterization of novel erythropoiesis stimulating protein (NESP)

Abstract

Studies on human erythropoietin (EPO) demonstrated that there is a direct relationship between the sialic acid-containing carbohydrate content of the molecule and its serum half-life and in vivo biological activity, but an inverse relationship with its receptor-binding affinity. These observations led to the hypothesis that increasing the carbohydrate content, beyond that found naturally, would lead to a molecule with enhanced biological activity. Hyperglycosylated recombinant human EPO (rHuEPO) analogues were developed to test this hypothesis. Darbepoetin alfa (novel erythropoiesis stimulating protein, NESP, ARANESP, Amgen Inc, Thousand Oaks, CA), which was engineered to contain 5 N-linked carbohydrate chains (two more than rHuEPO), has been evaluated in preclinical animal studies. Due to its increased sialic acid-containing carbohydrate content, NESP is biochemically distinct from rHuEPO, having an increased molecular weight and greater negative charge. Compared with rHuEPO, it has an approximate 3-fold longer serum half-life, greater in vivo potency, and can be administered less frequently to obtain the same biological response. NESP is currently being evaluated in human clinical trials for treatment of anaemia and reduction in its incidence.

References 37

1. 1.

   Broudy V. C., Lin N., Egrie J., de Haën C., Weiss T., Papayannopoulou T., Adamson J. W. Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide. Proc Natl Acad Sci U S A. 1988;85(17):6513-6517.

   Not in our library10.1073/pnas.85.17.6513

2. 2.

   Browne J. K., Cohen A. M., Egrie J. C., Lai P. H., Lin F. K., Strickland T., Watson E., Stebbing N. Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol. 1986;51(Pt 1):693-702.

   Not in our library10.1101/sqb.1986.051.01.082

3. 3.

   Cazzola M., Mercuriali F., Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood. 1997;89(12):4248-4267.

   Not in our library

4. 4.

   Cheetham J. C., Smith D. M., Aoki K. H., Stevenson J. L., Hoeffel T. J., Syed R. S., Egrie J., Harvey T. S. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol. 1998;5(10):861-866.

   Not in our library10.1038/2302

5. 5.

   Cumming D. A. Glycosylation of recombinant protein therapeutics: control and functional implications. Glycobiology. 1991;1(2):115-130.

   Not in our library10.1093/glycob/1.2.115

6. 6.

   D'Andrea A. D., Lodish H. F., Wong G. G. Expression cloning of the murine erythropoietin receptor. Cell. 1989;57(2):277-285.

   Not in our library10.1016/0092-8674(89)90965-3

7. 7.

   Davis J. M., Arakawa T., Strickland T. W., Yphantis D. A. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry. 1987;26(9):2633-2638.

   Not in our library10.1021/bi00383a034

8. 8.

   Delorme E., Lorenzini T., Giffin J., Martin F., Jacobsen F., Boone T., Elliott S. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry. 1992;31(41):9871-9876.

   Not in our library10.1021/bi00156a003

9. 9.

   Dordal M. S., Wang F. F., Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology. 1985;116(6):2293-2299.

   Not in our library10.1210/endo-116-6-2293

10. 10.

    Dubé S., Fisher J. W., Powell J. S. Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J Biol Chem. 1988;263(33):17516-17521.

    Not in our library

11. 11.

    Egrie J. C., Strickland T. W., Lane J., Aoki K., Cohen A. M., Smalling R., Trail G., Lin F. K., Browne J. K., Hines D. K. Characterization and biological effects of recombinant human erythropoietin. Immunobiology. 1986;172(3-5):213-224.

    Not in our library10.1016/s0171-2985(86)80101-2

12. 12.

    Eschbach J. W., Abdulhadi M. H., Browne J. K., Delano B. G., Downing M. R., Egrie J. C., Evans R. W., Friedman E. A., Graber S. E., Haley N. R. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111(12):992-1000.

    Not in our library10.7326/0003-4819-111-12-992

13. 13.

    Eschbach J. W., Egrie J. C., Downing M. R., Browne J. K., Adamson J. W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73-78.

    Not in our library10.1056/nejm198701083160203

14. 14.

    Evans R. W., Rader B., Manninen D. L. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA. 1990;263(6):825-830.

    Not in our library

15. 15.

    Fukuda M. N., Sasaki H., Lopez L., Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood. 1989;73(1):84-89.

    Not in our library

16. 16.

    Goldwasser E., Kung C. K., Eliason J. On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem. 1974;249(13):4202-4206.

    Not in our library

17. 17.

    Higuchi M., Oh-eda M., Kuboniwa H., Tomonoh K., Shimonaka Y., Ochi N. Role of sugar chains in the expression of the biological activity of human erythropoietin. J Biol Chem. 1992;267(11):7703-7709.

    Not in our library

18. 18.

    Krantz S. B. Erythropoietin. Blood. 1991;77(3):419-434.

    Not in our library

19. 19.

    LOWY P. H., KEIGHLEY G., BORSOOK H. Inactivation of erythropoietin by neuraminidase and by mild substitution reactions. Nature. 1960;185:102-103.

    Not in our library10.1038/185102a0

20. 20.

    Lacombe C., Mayeux P. Biology of erythropoietin. Haematologica. 1998;83(8):724-732.

    Not in our library

21. 21.

    Lai P. H., Everett R., Wang F. F., Arakawa T., Goldwasser E. Structural characterization of human erythropoietin. J Biol Chem. 1986;261(7):3116-3121.

    Not in our library

22. 22.

    Lodish H. F., Hilton D. J., Klingmüller U., Watowich S. S., Wu H. The erythropoietin receptor: biogenesis, dimerization, and intracellular signal transduction. Cold Spring Harb Symp Quant Biol. 1995;60:93-104.

    Not in our library10.1101/sqb.1995.060.01.012

23. 23.

    Lukowsky W. A., Painter R. H. Studies on the role of sialic acid in the physical and biological properties of erythropoietin. Can J Biochem. 1972;50(8):909-917.

    Not in our library10.1139/o72-127

24. 24.

    Macdougall I. C., Gray S. J., Elston O., Breen C., Jenkins B., Browne J., Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10(11):2392-2395.

    Not in our library10.1681/asn.v10112392

25. 25.

    Markham A., Bryson H. M. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs. 1995;49(2):232-254.

    Not in our library10.2165/00003495-199549020-00008

26. 26.

    Miyake T., Kung C. K., Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977;252(15):5558-5564.

    Not in our library

27. 27.

    Narhi L. O., Arakawa T., Aoki K. H., Elmore R., Rohde M. F., Boone T., Strickland T. W. The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem. 1991;266(34):23022-23026.

    Not in our library

28. 28.

    Recny M. A., Scoble H. A., Kim Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem. 1987;262(35):17156-17163.

    Not in our library

29. 29.

    Sasaki H., Bothner B., Dell A., Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem. 1987;262(25):12059-12076.

    Not in our library

30. 30.

    Sasaki H., Ochi N., Dell A., Fukuda M. Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. Biochemistry. 1988;27(23):8618-8626.

    Not in our library10.1021/bi00423a017

31. 31.

    Skehel J. J., Stevens D. J., Daniels R. S., Douglas A. R., Knossow M., Wilson I. A., Wiley D. C. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci U S A. 1984;81(6):1779-1783.

    Not in our library10.1073/pnas.81.6.1779

32. 32.

    Sowade B., Sowade O., Möcks J., Franke W., Warnke H. The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med. 1998;1(2):303-314.

    Not in our library10.3892/ijmm.1.2.303

33. 33.

    Spivak J. L., Hogans B. B. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood. 1989;73(1):90-99.

    Not in our library

34. 34.

    Syed R. S., Reid S. W., Li C., Cheetham J. C., Aoki K. H., Liu B., Zhan H., Osslund T. D., Chirino A. J., Zhang J. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature. 1998;395(6701):511-516.

    Not in our library10.1038/26773

35. 35.

    Takeuchi M., Takasaki S., Miyazaki H., Kato T., Hoshi S., Kochibe N., Kobata A. Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J Biol Chem. 1988;263(8):3657-3663.

    Not in our library

36. 36.

    Tsuda E., Goto M., Murakami A., Akai K., Ueda M., Kawanishi G., Takahashi N., Sasaki R., Chiba H., Ishihara H. Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins. Biochemistry. 1988;27(15):5646-5654.

    Not in our library10.1021/bi00415a038

37. 37.

    Winearls C. G., Oliver D. O., Pippard M. J., Reid C., Downing M. R., Cotes P. M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986;2(8517):1175-1178.

    Not in our library10.1016/s0140-6736(86)92192-6

Cited by papers we hold 3

• Evaluation of the management of anemia in hemodialysis patients in Lebanon · 2017
  Not checked
• Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications · 2016
  No notice
• Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy · 2002
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.